Abstract
Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study. The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Cetuximab / adverse effects
-
Colonic Neoplasms* / drug therapy
-
Colorectal Neoplasms* / drug therapy
-
Colorectal Neoplasms* / pathology
-
Fluorouracil / adverse effects
-
Humans
-
Leucovorin / adverse effects
-
Neoplasm Metastasis / drug therapy
-
Organoplatinum Compounds / adverse effects
-
Prospective Studies
-
Rectal Neoplasms* / chemically induced
-
Rectal Neoplasms* / drug therapy
Substances
-
Organoplatinum Compounds
-
Cetuximab
-
Leucovorin
-
Fluorouracil